Literature DB >> 28806246

Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?

Ana María García Vicente1, Ángel Soriano Castrejón, Ruth Alvarez Cabellos, Belén Sanchez Gil, Nicolás Mohedano Mohedano.   

Abstract

We present 3 cases of patients with castration-resistant prostate cancer and bone metastases treated with Ra, belonging to our prospective and multicenter ChoPET-Rad study. All patients underwent clinical, hematological, and biochemical monitoring between each Ra administration. Initial and follow-up F-fluorocholine PET/CT and Tc-biphosphonate bone scintigraphy were performed previously and after the third Ra administration. Both techniques correctly established the response to treatment, in agreement to the biochemical response, although differences in the disease expression (concordant and discordant patterns) were found because of the different radiotracer biodistribution and molecular information derived from them.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28806246     DOI: 10.1097/RLU.0000000000001799

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  2 in total

1.  The Potential Use of 11C-Choline Positron Emission Tomography/Computed Tomography to Monitor the Treatment Effects of Radium-223 in a Patient with Prostate Cancer.

Authors:  Kazuhiro Kitajima; Shingo Yamamoto; Norihiko Kamikonya; Yukako Nakanishi; Yusuke Yamada; Takahiko Hashimoto; Toru Suzuki; Shuken Go; Akihiro Kanematsu; Michio Nojima; Koichiro Yamakado
Journal:  Cureus       Date:  2018-07-09

2.  Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride.

Authors:  Ana María García Vicente; Mariano Amo-Salas; Javier Cassinello Espinosa; Roberto Gómez Díaz; Ángel Soriano Castrejón
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.